Condition category
Signs and Symptoms
Date applied
Date assigned
Last edited
Retrospectively registered
Overall trial status
Recruitment status
No longer recruiting
Publication status
Results overdue

Plain English Summary

Background and study aims
Clinical studies and experiments with Rhodiola rosea extract have demonstrated significant relief of stress, fatigue and exhaustion. The aim of this study is to obtain information about the effects and safety of Rhodiola rosea extract in subjects with chronic fatigue symptoms.

Who can participate?
Male or female outpatients aged 18 to 60 years with clinically evaluated, unexplained persistent or relapsing fatigue symptoms lasting for at least 2 months.

What does the study involve?
Participants will undergo a physical examination, electrocardiogram (ECG) and laboratory tests including blood sampling at the beginning and the end of the trial. All participants will be treated with Rhodiola rosea extract. We will measure the effects of treatment on fatigue, sleep, concentration and level of activity.

What are the possible benefits and risks of participating?
Published clinical studies reported no adverse events for participants under active treatment related to Rhodiola rosea extract.

Where is the study run from?
The study is running in 10 sites/university based clinics in Ukraine.

When is the study starting and how long is it expected to run for?
The study ran from December 2011 to August 2012.

Who is funding the study?
Dr. Willmar Schwabe GmbH & Co. KG (Germany).

Who is the main contact?
Mrs Anna Wacker

Trial website

Contact information



Primary contact

Dr Igor Tartakovsky


Contact details

Dr. Willmar Schwabe GmbH & Co. KG
Willmar-Schwabe-Str. 4

Additional identifiers

EudraCT number number

Protocol/serial number


Study information

Scientific title

Rhodiola rosea Extract WS® 1375 in subjects with chronic fatigue symptoms


Study hypothesis

The objective of this clinical trial is to describe therapy effects, safety and tolerability of Rhodiola rosea Extract WS® 1375 in subjects with chronic fatigue symptoms.

Ethics approval

Central Ethics Committee, Ministry of Health Ukraine, 05/07/2011, ref: 5.12-753/KE dtd

Study design

Open multicentre single-arm phase III study

Primary study design


Secondary study design


Trial setting


Trial type


Patient information sheet

Not available in web format, please use the contact details below to request a patient information sheet


Chronic fatigue symptoms


2 x 200 mg Rhodiola rosea Extract WS® 1375

The following self-rating scales and questionnaires will be used in this trial:
1. Multidimensional Fatigue Inventory 20 (MFI-20) – assessment of the chronic fatigue symptoms
2. Three Numerical Analogue Scales of chronic fatigue symptoms (postexertional malaise, impaired memory and concentration; unrefreshing sleep)
3. Sheehan Disability Scale – assessment of the impairment of daily living and reduction in previous levels of activity
4. Number Connecting Test – assessment of memory and concentration
5. Pittsburgh Sleep Quality Index (PSQI) – assessment of sleep quality
6. Recent Perceived Stress Questionnaire (PSQ-R) – assessment of stress level
7. Beck’s Depression Inventory (BDI-II) – assessment of depression
8. Clinical Global Impression (CGI) - physician rated, for changes from baseline as well as as for the assessment of the tolerability

The completion of the patient self-rating scales, including the NCT test with the stop watch will take estimated between 40 and 60 minutes per study visit. Not for all visits all test are required, in this case the estimated time for the completion of the questionnaires will be shorter, about 30 minutes.

Intervention type



Phase III

Drug names

Primary outcome measure

Treatment effect outcome variables:
1. Multidimensional Fatigue Inventory 20 (MFI-20)
2. Three NASs of Chronic Fatigue Symptoms
3. Pittsburgh Sleep Quality Index (PSQI)
4. Numbers Connecting Test
5. Sheehan Disability Scale
6. Recent Perceived Stress Questionnaire (R-PS Qustionnaire)
7. Beck’s Depression Inventory (BDI-II)
8. Clinical Global Impressions (CGI)

Safety outcome variables:
1. Physical examination
2. Vital signs
3. Adverse events
4. Laboratory tests

Secondary outcome measures

No secondary outcome measures

Overall trial start date


Overall trial end date


Reason abandoned (if study stopped)


Participant inclusion criteria

1. Male or female outpatients aged 18 to 60 years (both inclusive)
2. Signed Informed consent in accordance with the legal requirements
3. Clinically evaluated, unexplained persistent or relapsing fatigue symptoms lasted at least 2 months that:
3.1. Is not the result of ongoing exertion
3.2. Is not substantially relieved by rest
3.3. Results in substantial reduction in previous levels of occupational, educational, social or personal activities
4. The following perceived Chronic Fatigue Symptoms listed below assessed as ≥5 on NASs:
4.1. Postexertional malaise (extreme prolonged exhaustion following physical or mental exertion) lasting more than 24 hours
4.2. Substantial impairment in short-time memory and concentration
4.3. Unrefreshing sleep
5. Multidimensional Fatigue Inventory 20 (MFI-20) score 7 or more for the sub-scales:
5.1. General fatigue
5.2. Physical fatigue
5.3. Mental fatigue
6. Sufficient language skills, readiness, and ability on the part of the patient to comply with the physician’s instructions, respond to all interview questions, and to fill in the self-assessment scales without evident difficulties and without the assistance of an interpreter.
7. Negative pregnancy test at Screening visit in females of childbearing potential (non-childbearing potential is defined as post-menopause for at least one year or surgical sterilization or hysterectomy at least three months before study start).

Participant type


Age group




Target number of participants

100 patients

Participant exclusion criteria

1. Participation in another experimental drug trial at the same time or within the past 12 weeks before enrolment
2. Current hospitalization of the patient
3. Beck’s Depression Inventory (BDI-II) item 9 ≥ 1
4. History or evidence of alcohol and/or substance abuse or dependence, particularly of sedatives, hypnotics and anxiolytics within the last 5 years
5. History of Axis I disorders according to DSM-IV at least one year before enrolment - the last episode must have been finished at least one year before enrolment. (Common Axis I disorders include major depression, anxiety disorders, bipolar disorder, ADHD, autism spectrum disorders, phobias, and schizophrenia. Major Depression is defined by BDI-II total score >19 at Screening.)
6. Non-medical psychiatric treatment (e.g., specific standardized psychotherapy) at least 4 weeks before the study.
7. Unacceptability to discontinue or likelihood to need medication during the study that is prohibited as concomitant treatment (specified in section 6). The following medication is not allowed during the study:
7.1. Any psychotropic drugs including CNS stimulants, tranquilizers / hypnotics (e.g. benzodiazepines, non-benzodiazepines like zopiclone or zolpidem, barbiturates), neuroleptics / antipsychotics, antidepressives, antiepileptics, antihistaminics, anti-emetics and nootropics
7.2. Long-term prophylactic treatment (e.g. lithium, carbamazepine)
7.3. Treatments for neuro-degenerative diseases
7.4. Central-acting antihypertensive medication (e.g. reserpine, clonidin, methyldopa), antihypertensive medication with guanethidine, guanoxan, prazosine
7.5. Beta-blockers (exception: stable dosage for at least 4 weeks)
7.6. Antiparkinson medication
7.7. Muscle relaxants
7.8. Analgetics of opiate type
7.9. Anesthetics
8. Clinical significant abnormality of ECG and/or laboratory value(s).
9. Any clinically relevant:
9.1. Hepatic, renal disorders (serum creatinine or serum ASAT, ALAT or Gamma GT above 3 times the upper limit of the reference range)
9.2. Cardiovascular diseases
9.3. Respiratory diseases
9.4. Metabolic disorder or progressive diseases as cancer (exception: prostate cancer T1N0M0 which does not require treatment within the next 7 months except hormone therapy)
9.5. Haematologic diseases
9.6. Cerebrovascular and neurologic diseases (epilepsy or a history of seizure disorder or treatment with anticonvulsants for epilepsy or seizures, Parkinson’s disease, multiple sclerosis, injury with residual neurologic deficits)
10. Any form of diabetes mellitus
11. Clinically significant anaemia
12. Clinically significant thyroid dysfunction as expressed by significant abnormality in TSH, T3 and/or T4 levels
13. Any acute or chronic form of infection including HIV infection or Lues of any stage (according to medical history or clinical signs and symptoms).
14. Known hypersensitivity to Rhodiola rosea extract.
15. Gastrointestinal disorders with uncertain absorption of orally administered drugs (e.g. partial or total gastrectomy, enterectomy, inflammatory bowel disease, celiac disease, symptomatic lactose intolerance, other disorders associated with chronic diarrhoea)
16. Pregnancy, lactation
17. Patients capable of childbearing if not using adequate contraception (intra-uterine devices, oral or injectable contraception)

Recruitment start date


Recruitment end date



Countries of recruitment


Trial participating centre

Dr. Willmar Schwabe GmbH & Co. KG

Sponsor information


Dr. Willmar Schwabe GmbH & Co. KG (Germany)

Sponsor details

Willmar-Schwabe-Str. 4

Sponsor type

Research organisation



Funder type

Research organisation

Funder name

Dr. Willmar Schwabe GmbH & Co. KG (Germany)

Alternative name(s)

Funding Body Type

Funding Body Subtype


Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Basic results (scientific)

Publication list

Publication citations

Additional files

Editorial Notes